Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.
Executive Summary
Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.
You may also be interested in...
Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.
Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.
Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.
Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.
Meningococcal Conjugate Vaccine Studies May Use Immunologic Correlates
Immunologic correlates may be used to predict protective efficacy of meningococcal conjugate vaccines, FDA's Vaccines and Related Biological Products Advisory Committee agreed at a Sept. 15 meeting in Bethesda, Md.